Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × OTHER × empagliflozin × Clear all

Phase

Status

Unknown 2 Terminated 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Cardiotoxicity 1

Interventions

Radiotherapy 297 Specimen Handling 292 Magnetic Resonance Spectroscopy 290 pembrolizumab 273 Cyclophosphamide 261 Cisplatin 234 Carboplatin 219 Blood Specimen Collection 216 Drug Therapy 208 Biopsy 176 Gemcitabine 163 venetoclax 159 Bevacizumab 159 Radiosurgery 153 Oxaliplatin 146 fludarabine 144 Nivolumab 144 Capecitabine 141 Paclitaxel 135 Standard of Care 125 Surgical Procedures, Operative 122 Fluorouracil 118 Dexamethasone 113 Surveys and Questionnaires 112 Docetaxel 102 Rituximab 101 tislelizumab 99 Radiation 98 Cytarabine 95 durvalumab 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271162 2025-11-21

EMPACT

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 3 Recruiting

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡